0
Clinical Investigations: PULMONARY |

Regular vs Ad-lib Albuterol for Patients Hospitalized With Acute Asthma*

Alpana Chandra, MD; Chang Shim, MD; Hillel W. Cohen, DrPH; Virginia Chung, MD; Diane Maggiore, MD; Kartik Mani, MBBS; Sunil Dhuper, MD
Author and Funding Information

*From the Division of Pulmonary Medicine (Drs. Chandra, Shim, Chung, Maggiore, and Dhuper), Jacobi Medical Center; Department of Epidemiology and Population Health (Dr. Cohen); and Department of Medicine (Dr. Mani), Albert Einstein College of Medicine, Bronx, NY.

Correspondence to: Chang Shim, MD, Jacobi Medical Center, 1400 Pelham Parkway S, Suite 5N-50, Bronx, NY 10461; e-mail: cshim107@aol.com



Chest. 2005;128(3):1115-1120. doi:10.1378/chest.128.3.1115
Text Size: A A A
Published online

Study objectives: Inhaled, short-acting β-agonists and systemic corticosteroids form the mainstay of therapy in acute asthma exacerbation. Asthma, however, is an inflammatory disease of the airways, and its underlying pathology is not impacted by short-acting β-agonists. While the efficacy of ad-lib β-agonist administration in outpatient management of asthma symptoms is well established, little data exist to support this strategy in patients with acute, severe asthma. We postulate that as long as patients hospitalized with severe asthma exacerbation receive systemic corticosteroids, regular, scheduled administration of short-acting β-agonists is unnecessary. Similar therapeutic outcomes can be achieved with the ad-lib administration of the short-acting β-agonists.

Design: Prospective, randomized, double-blind, placebo-controlled trial.

Setting: Pulmonary floor of a 600-bed municipal hospital.

Patients or participants: Sixty-two patients hospitalized for acute asthma.

Interventions: Patients were randomized to receive either albuterol nebulizations (regular albuterol group) or saline solution nebulizations (ad-lib group) every 4 h with management of breakthrough symptoms with albuterol metered-dose inhaler or nebulizations for both groups. All patients received systemic corticosteroids. Peak expiratory flows, asthma symptoms, and need for rescue bronchodilator were followed up on each patient until discharge.

Results: There was no significant difference in the length of hospitalization (median length, 48 h for ad-lib group vs 57.5 h for regular albuterol group, p = 0.82), rate of improvement in peak flow, or symptoms between the two groups. Ad-lib β-agonist use compared to regular albuterol scheduled use resulted in a significant reduction in the total number of albuterol treatments administered (median, 7 treatments vs 19 treatments, p = 0.001) during hospitalization.

Conclusions: In the management of asthma exacerbation, ad-lib administration of albuterol is therapeutically as effective as regular, scheduled administration. This method of drug administration also reduces the total dose of β-agonists received by the hospitalized patient.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543